Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 6.15% in last session and finished the day at $5.35. Traded volume was 885.2K shares in the last session and the average volume of the stock remained 1.66million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.50%.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. (NASDAQ:SRPT) common stock between July 24, 2013 through November 12, 2013. Sarepta Therapeutics Inc (NASDAQ:SRPT) rose 6.99 percent to $25.71 Tuesday on volume of 903.2K shares. The intra-day range of the stock was $24.26 to $25.98. Sarepta Therapeutics Inc (NASDAQ:SRPT) has a market capitalization of $971.20million.

Northwest Biotherapeutics Inc (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after Northwest Biotherapeutics Inc (NASDAQ: NWBO)’s public presentation of significant positive news about all of the Company’s programs. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s stock on Apr 01, 2014 reported a increase of 6.22% to the closing price of $7.69. Its fifty two weeks range is $3.10 -$10.64. The total market capitalization recorded $333.77million. The overall volume in the last trading session was 965.5K shares. In its share capital, NMBO has 43.40million outstanding shares.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals Inc (NASDAQ:PGNX). On Tuesday, shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) advanced 6.36% to close the day at $4.35. Company return on investment (ROI) is -53.30% and its monthly performance is recorded as -7.45%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly revenue growth is -18.84%.